Zheng Quan Ri Bao·2025-06-22 16:46Core Insights - The global obesity drug market is projected to exceed $100 billion by 2030, driven by the increasing number of obese individuals worldwide [1][2] - Major pharmaceutical companies, both multinational and domestic, are intensifying their efforts in the obesity drug sector, leading to fierce competition in technology, capital, and market presence [2] Domestic Drug Development - Domestic companies are making significant progress in the development of obesity drugs, with recent approvals for clinical trials of GLP-1 class innovative drugs by Changshan Biochemical Pharmaceutical and Guangdong Zhongsheng Pharmaceutical [3] - Changshan Biochemical has received approval for clinical trials of its injection for weight loss, while Guangdong Zhongsheng has completed the first participant enrollment for its innovative peptide drug RAY1225 in a Phase III trial [3] - The global sales of GLP-1 receptor agonists (GLP-1RA) are expected to exceed $150 billion by 2031, indicating a strong market potential [3] Market Dynamics - The global obesity drug market is currently dominated by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, with semaglutide projected to generate sales of 6.6 billion yuan in China by 2024 [4] - The domestic GLP-1 drug market is expected to surpass 20 billion yuan by 2030, with several domestic GLP-1 drugs already approved [5] - The influx of domestic companies into the obesity drug market reflects a consensus on the explosive growth potential of the sector, although it may lead to intensified price competition [5] Competitive Landscape - Chinese pharmaceutical companies are leveraging multi-target innovation and differentiated development strategies to gain a competitive edge in the GLP-1 market [6] - Jiangsu Hengrui Medicine's dual-target drug HRS9531 has shown superior weight loss results compared to existing treatments, indicating the potential for domestic products to compete internationally [6] - Cross-border collaborations in the GLP-1 field are increasing, with companies like Federated Pharmaceutical and Hansoh Pharmaceutical engaging in licensing agreements to expand their market reach [6][7] Future Outlook - The obesity drug market is expected to undergo a significant reshuffle in the next 3 to 5 years, with products that demonstrate clinical value and technological barriers likely to prevail [7]